naringenin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Naringenin consumption significantly reduced percentages of NAFLD grades (P < .001), as well as, serum levels of triglyceride (TG) (P < .001), total cholesterol (TC) (P = .01), and low-density lipoprotein (LDL) (P = .02) and increased serum level of high-density lipoprotein (HDL) (P = .02) compared with the control group.”
Quoted verbatim from Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 100 mg capsules twice a day, before lunch and dinner
- Population
- 44 overweight/obese patients with NAFLD, placebo-controlled
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.2021PMID:34516703Permalink
Keep reading
- Everything the graph holds on naringenin
- Every compound studied against Triglycerides
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PM1DGN2WB57XH1430V13EJ